» Articles » PMID: 32977678

The Role of Vesicle Trafficking Defects in the Pathogenesis of Prion and Prion-Like Disorders

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Sep 26
PMID 32977678
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Prion diseases are fatal and transmissible neurodegenerative diseases in which the cellular form of the prion protein 'PrP', misfolds into an infectious and aggregation prone isoform termed PrP, which is the primary component of prions. Many neurodegenerative diseases, like Alzheimer's disease, Parkinson's disease, and polyglutamine diseases, such as Huntington's disease, are considered prion-like disorders because of the common characteristics in the propagation and spreading of misfolded proteins that they share with the prion diseases. Unlike prion diseases, these are non-infectious outside experimental settings. Many vesicular trafficking impairments, which are observed in prion and prion-like disorders, favor the accumulation of the pathogenic amyloid aggregates. In addition, many of the vesicular trafficking impairments that arise in these diseases, turn out to be further aggravating factors. This review offers an insight into the currently known vesicular trafficking defects in these neurodegenerative diseases and their implications on disease progression. These findings suggest that these impaired trafficking pathways may represent similar therapeutic targets in these classes of neurodegenerative disorders.

Citing Articles

Single-Cell Cortical Transcriptomics Reveals Common and Distinct Changes in Cell-Cell Communication in Alzheimer's and Parkinson's Disease.

Bars S, Glaab E Mol Neurobiol. 2024; 62(3):2655-2673.

PMID: 39143450 PMC: 11790751. DOI: 10.1007/s12035-024-04419-7.


The ESCRT Pathway's Role in Prion Diseases and Beyond.

Taha H J Neurosci. 2023; 43(46):7727-7729.

PMID: 37968123 PMC: 10648497. DOI: 10.1523/JNEUROSCI.1143-23.2023.


Extracellular chaperone networks and the export of J-domain proteins.

Braun J J Biol Chem. 2022; 299(2):102840.

PMID: 36581212 PMC: 9867986. DOI: 10.1016/j.jbc.2022.102840.


Prion Pathogenesis Revealed in a Series of the Special Issues "Prions and Prion Diseases".

Sakaguchi S Int J Mol Sci. 2022; 23(12).

PMID: 35742934 PMC: 9224285. DOI: 10.3390/ijms23126490.

References
1.
Poteryaev D, Datta S, Ackema K, Zerial M, Spang A . Identification of the switch in early-to-late endosome transition. Cell. 2010; 141(3):497-508. DOI: 10.1016/j.cell.2010.03.011. View

2.
Horonchik L, Tzaban S, Ben-Zaken O, Yedidia Y, Rouvinski A, Papy-Garcia D . Heparan sulfate is a cellular receptor for purified infectious prions. J Biol Chem. 2005; 280(17):17062-7. DOI: 10.1074/jbc.M500122200. View

3.
Ghaemmaghami S, Phuan P, Perkins B, Ullman J, May B, Cohen F . Cell division modulates prion accumulation in cultured cells. Proc Natl Acad Sci U S A. 2007; 104(46):17971-6. PMC: 2084281. DOI: 10.1073/pnas.0708372104. View

4.
Small S, Kent K, Pierce A, Leung C, Kang M, Okada H . Model-guided microarray implicates the retromer complex in Alzheimer's disease. Ann Neurol. 2005; 58(6):909-19. DOI: 10.1002/ana.20667. View

5.
Muller M, Goody R . Molecular control of Rab activity by GEFs, GAPs and GDI. Small GTPases. 2017; 9(1-2):5-21. PMC: 5902221. DOI: 10.1080/21541248.2016.1276999. View